Detalhe da pesquisa
1.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood
; 131(14): 1522-1531, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358182
2.
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
JAMA Neurol
; 80(3): 298-307, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689214
3.
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
Expert Opin Biol Ther
; 23(12): 1287-1297, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38044885
4.
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects.
Pharmacol Res Perspect
; 7(5): e00503, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31417680
5.
Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects.
Pharmacol Res Perspect
; 7(5): e00507, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31417681